

CLAIMS

1. The use of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence

5

MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIIFV VGIFG

or a fragment thereof, in the preparation of a medicament for the treatment of cancer.

10 2. The use of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence

MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIIFV VGIFG

15

or a fragment thereof, in the preparation of a medicament for the treatment of vascular smooth muscle (VSM) cell proliferation.

20 3. A use as claimed in claim 1 or claim 2, in which the monoclonal antibody is raised against the peptide EDGITKRIQDD.

4. A use as claimed in any one of claims 1 to 3, in which the monoclonal antibody is a humanised antibody.

25 5. A use as claimed in any one of claims 1 to 3, in which the monoclonal antibody is 6313/G2 produced by the hybridoma cell line designated by accession no. 93072117.

30 6. A method for the treatment of cancer comprising administration to a subject in need thereof a therapeutic amount of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the amino acid sequence

MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG

or a fragment thereof.

5

7. A method for the treatment of vascular smooth muscle cell proliferation comprising administration to a subject in need thereof a therapeutic amount of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the amino acid sequence

10

MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG

or a fragment thereof.

15

8. A method as claimed in claim 6 or claim 7, in which the monoclonal antibody is raised against the peptide EDGIKRIQDD

9. A method as claimed in any one of claims 6 to 8, in which the monoclonal antibody is a humanised monoclonal antibody.

20

10. A method as claimed in any one of claims 6 to 8, in which the monoclonal antibody is 6313/G2 produced by the hybridoma cell line designated by accession no. 93072117.

25

11. The use of a peptide sequence comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence

MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG

30

or a fragment thereof, in the preparation of a medicament for the treatment of cancer.

12. A vaccine composition comprising a peptide sequence comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence

MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG

5

or a fragment thereof.

13. A vaccine composition as claimed in claim 11, in which the peptide is conjugated to a carrier protein.